688180 君实生物
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额(329,388)(1,433,841)(2,004,982)(1,776,201)(605,050)
投资活动产生之现金流量净额(552,854)(892,782)(933,191)(437,213)(1,917,802)
筹资活动产生之现金流量净额1,384,3641,023,146711,8284,613,4782,665,686
汇率变动对现金及现金等价物的影响37612,0157,55192,266(23,226)
现金及现金等价物净增加/(减少)502,498(1,291,463)(2,218,794)2,492,331119,607
期初现金及现金等价物余额2,486,6793,778,1425,996,9363,504,6053,384,998
期末现金及现金等价物余额2,989,1772,486,6793,778,1425,996,9363,504,605